NEOGENOMICS INC (NEO) FY2025 10-K Annual Report
NEOGENOMICS INC (NEO) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 17, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
NEOGENOMICS INC FY2025 10-K Analysis
Business Overview
- • Core business: oncology-focused diagnostic testing and consultative services, including molecular and precision cancer testing
- • Emphasis on growth in therapy selection and Molecular Residual Disease (MRD) testing with launches under a 2026 launch excellence program
- • Strategic expansion into community oncology market leveraging partnerships for accelerated topline growth
- • Largest molecular testing panels include PanTracer and Neo Comprehensive portfolios with NGS capabilities; Inivata acquisition (2021) bolsters liquid biopsy MRD tech
- • 2026 focus on driving operational efficiency via automation, customer experience improvements, and culture with enhanced collaboration and accountability
Management Discussion & Analysis
- • Revenue $727.3M in 2025, up 10.1% YoY or $66.8M, driven by higher test volumes, higher value tests, reimbursement, and Pathline acquisition
- • Gross profit $314.3M, margin 43.2% in 2025 vs 43.9% in 2024, a 0.7% margin decline mainly from Pathline acquisition and rising costs
- • Best segment: clinical molecular and NGS testing driving growth; worst segment: lower non-clinical revenue due to macro clinical trial trends
- • Adjusted EBITDA $43.4M in 2025, up 9.5% or $3.7M YoY; G&A $273.3M (37.6% of revenue) increased 5.2% or $13.6M; sales & marketing $92.0M up 8.7%
- • No restructuring charges in 2025 vs $6.7M in 2024; R&D expense $37.1M (5.1% of revenue), up 19%; expecting increased R&D investment going forward
- • Management plans to grow via precision diagnostics, therapy selection, MRD testing, community oncology expansion, and efficiency through automation
- • Regulatory risk: FDA LDT oversight uncertain after 2025 court ruling vacating FDA rule; potential future FDA changes could increase compliance costs
- • No significant expected 2026 revenue impact from regulatory changes; continued investments in test menu expansion, IT, automation, and sales force growth
Risk Factors
- • FDA potential regulation of Laboratory Developed Tests requiring clinical trials and approvals, risking operational disruptions and costs
- • Global conflicts and political unrest posing business disruption risks with no specific regional revenue exposure disclosed
- • Capacity constraints risk from inability to scale personnel and systems impacting turnaround times and client retention
- • Intense competition from Quest Diagnostics, Guardant Health, and Myriad Genetics increasing price pressure and market share risk
- • Servicing $2028 Convertible Notes may strain cash flow and limit financial flexibility impacting operational funding
NEOGENOMICS INC FY2025 Key Financial MetricsXBRL
Revenue
$727M
▲ +10.1% YoY
Net Income
-$108M
▼ -37.2% YoY
Gross Margin
43.2%
▼ -71bp YoY
Operating Margin
-15.9%
▼ -199bp YoY
Net Margin
-14.9%
▼ -293bp YoY
ROE
-12.9%
▼ -419bp YoY
Total Assets
$1.4B
▼ -17.0% YoY
Operating Cash Flow
$5M
▼ -25.5% YoY
Source: XBRL data from NEOGENOMICS INC FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on NEOGENOMICS INC
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.